The company’s scientific direction was formally established with rheumatoid arthritis selected as the lead indication. This decision was based on the significant unmet medical need in autoimmune diseases and the growing body of preclinical literature describing THCA’s interactions with inflammatory signaling pathways, including PPARγ, NF-κB, TNF-α, IL-6, and IL-1β.